Allogeneic ABCB5-positive Stem Cells for Treatment of CVU

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

31 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-11-16

Study Completion Date

2020-06-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this clinical trial is to investigate the efficacy (by monitoring the wound size reduction of Chronic Venous Ulcers) and safety (by monitoring adverse events) of the medicinal product to be studied after two applications on the wound surface in patients with Chronic Venous Ulcers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Therapy-resistant CVU (Phase III)

NCT06489028

Venous Leg Ulcer

ACTIVE_NOT_RECRUITING PHASE3

Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of CVU (Phase IIb)

NCT04971161

Skin Ulcer Venous Stasis Chronic

COMPLETED PHASE2

Clinical Trial to Investigate Efficacy and Safety of the IMP in Patients With Non Healing Wounds Originating From Ulcers

NCT02742844

Skin Ulcer Venous Stasis Chronic

TERMINATED PHASE1/PHASE2

Allogeneic ABCB5-positive Stem Cells for Treatment of DFU "Malum Perforans"

NCT03267784

Diabetic Neuropathic Ulcer

COMPLETED PHASE1/PHASE2

Study of VF001-DP in Patients With Chronic Venous Leg Ulcers

NCT02973893

Ulcer Leg Ulcer Varicose Ulcer +5 more

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an interventional, single arm, phase I/IIa clinical trial to investigate the efficacy and safety of allogeneic ABCB5-positive mesenchymal stem cells (MSCs) on wound healing in patients with chronic venous ulcer (CVU). Allogeneic MSCs will be isolated ex vivo and will be expanded in vitro. The IMP incorporating the ABCB5-positive MSCs will then be applied on the wound surface of CVU under local anesthesia (on Day 0 and Week 6.1).

Wound measurements from Visit (V) 2 and V9 will be used to determine the cell amount for the IMP treatments on V3 and V10, respectively.

Patients are followed up for efficacy for 3 months which allows to distinguish actual wound healing from transient wound coverage.

The wound healing process will be documented by standardized photography. The wound size evaluation will start on the day of the first change of wound dressing. The quality of the wound healing process will be assessed on the basis of formation of granulation tissue, epithelialization and wound exudation.

Pain will be assessed using a numerical rating scale and quality of life will be investigated with standardized and validated questionnaires. To assess long-term safety of allo-APZ2-CVU three follow-up visits at Months 6, 9 and 12 after the first IMP applications are included.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Skin Ulcer Venous Stasis Chronic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Interventional, single arm, multicenter, phase I/IIa clinical trial

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

allo-APZ2-CVU

Application of IMP on patients wound

Group Type EXPERIMENTAL

allo-APZ2-CVU

Intervention Type BIOLOGICAL

Suspension of ABCB5-positive mesenchymal stem cells

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

allo-APZ2-CVU

Suspension of ABCB5-positive mesenchymal stem cells

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female patients aged 35 to 85 years;
2. Chronic venous leg ulcer (as defined by the current AWMF guidelines: therapy resistant ulcer that shows no improvement within 3 months despite of optimal phlebological therapies or is not healed within 12 months) diagnosed by doppler ultrasonography (DUS), ankle brachial index (ABI, 0.9-1.3), physical examination and dermatological review;
3. Wound size of target ulcer between 1.5 and 100 cm2 measured by a standardized photography at the screening visits (Visit 1 and Visit 2);
4. Wound location below knee;
5. If patients are suffering from 2 or more ulcers at the same extremity, the target ulcer has to be separated by a minimum bridge of 1 cm of epithelialized skin from other ulcers (the largest ulcer should be the target ulcer, if not decided otherwise at discretion of the investigator; the target ulcer is defined at Visit 1);
6. Body mass index (BMI) between 20 and 45 kg/m²;
7. Patients understand the nature of the procedure and are providing written informed consent prior to any clinical trial procedure;
8. Women of childbearing potential must have a negative blood pregnancy test at Visit 1
9. Women of childbearing potential and their partner must be willing to use highly effective contraceptive methods during the course of the clinical trial.

Exclusion Criteria

1. Evidence of the ulcer extending to the underlying muscle, tendon, or bone;
2. Current use of systemic steroid medication above Cushing threshold dose (\>7.5 mg/d prednisone or equivalent);
3. Diabetes mellitus that has to be evaluated by blood test (Haemoglobin A1c \[HbA1c\] \>7.5%);
4. Peripheral Artery Disease (PAD) including claudication with need of treatment;
5. Acute deep vein thrombosis (maximum 30 days from diagnosis) or a still untreated deep vein thrombosis;
6. Unable to tolerate leg ulcer compression bandage;
7. Infection of the target ulcer requiring treatment as judged clinically;
8. Any chronic dermatological disorders diagnosed at the investigator's discretion;
9. Skin disorders, unrelated to the ulcer, that are present adjacent to the target wound;
10. Current use of medications that influence wound healing: systemic immunosuppressives, cytotoxic medicinal products, and systemic steroids (above Cushing-threshold level);
11. Known abuse of alcohol, drugs, or medicinal products;
12. Cancerous or pre-cancerous lesions adjacent to the target wound;
13. Patients anticipated to be unwilling or unable to comply with the requirements of the protocol;
14. Pregnant or lactating women;
15. Systemic infectious disease diagnosed by serology testing human immunodeficiency virus (HIV˗1, HIV-2);
16. Any known allergies to components of the IMP;
17. Prior surgical procedures such as bypass or mesh-graft treatment within 2 months prior to Visit 1;
18. Patients with significant ulcer healing or wound size enlargement of more than 25% at Visit 2 compared to Visit 1;
19. Treatment of target ulcer with active wound care agents (e.g. iruxol, local antibiotics or silver dressings), which have not been paused 14 days before IMP application;
20. Current or previous (within 30 days of enrollment) treatment with another IMP, or participation and/or under follow-up in another clinical trial;
21. Previous participation in this clinical trial (except for screening failures due to an inclusion or exclusion criterion);
22. Evidence of any other medical conditions (such as psychiatric illness, physical examination, or laboratory findings) that may interfere with the planned treatment, affect the patient's compliance, or place the patient at high risk of complications related to the treatment;
23. Employees of the sponsor, or employees or relatives of the investigator.

Minimum Eligible Age

35 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No